ReviewInternational journal of nanomedicine2025
Advances in the Drug Delivery Systems for Psoriasis Topical Therapy.
Review in International journal of nanomedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Nanotechnology based topical drug delivery systems for psoriasis addressing current strategies clinical progress and manufacturing challenges.Discover nano · 2026Review
- Increased Anti-Psoriatic Effect of Anti-Inflammatory Dendrimers Using Fluid Catanionic Vesicle-Based Topical Formulations.Advanced healthcare materials · 2026Article
- The multifaceted role of NF-κB signaling in psoriasis: from inflammatory amplification to epidermal remodeling.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Psoriasis (PSO) is an immune-related skin disease featured by rapid and excessive cell growth leading to thick red scaly skin plaques. The main treatment strategy for PSO involves using anti-inflammatory drugs, immunosuppressants, etc, to relieve symptoms, suppress inflammation, and retard the overgrowth and division of skin cells. However, these drugs generally have disadvantages such as poor targeting, short half-life, low bioavailability, significant toxic side effects, etc. which impose a huge physiological and pathological burden on patients. Recently, the use of delivery systems to topical deliver drugs to the damaged psoriatic skin sites has received extensive attention from researchers. These systems promote drug stability, enhance drug penetration, and improve drug efficacies. The continuous development of various multifunctional topical delivery systems provides more therapeutic ideas for the cure of PSO. Based on this, this manuscript reviews the research progress of various delivery systems (including nanoparticles, hydrogels, microneedles, micelles, dendrimers, liposomes, nanoemulsions, vesicles, etc.) for PSO topical therapy and summarizes their development status in clinical treatment. It's expected to provide reference for the design of novel topical delivery systems and promote the development of PSO therapy methods.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.